



IC05 Rec'd PCT/PTO 16 SEP 2005

PCT

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88600

Si-Young CHO, et al.

Appln. No.: 10/539,012

Group Art Unit: Unassigned

Confirmation No.: Unassigned

Examiner: Unassigned

Filed: June 15, 2005

For: AN AGENT FOR CONTROLLING BCL-2 EXPRESSION COMPRISING
GINSENOSIDE F1 AS AN ACTIVE COMPONENT

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. Korean Patent Application No. 2003-0094523, published December 18, 2003, to Amorepacific Corporation, with English Abstract. This reference was identified in the International Search Report and was listed on the PTO/SB/08 A & B submitted to the U.S. Patent and Trademark Office on June 15, 2005.
2. Korean Patent Application No. 2003-0060027, published July 12, 2003, to Amorepacific Corporation with English Abstract. This reference was identified in the International Search Report and was listed on the PTO/SB/08 A & B submitted to the U.S. Patent and Trademark Office on June 15, 2005.
3. Martin D. Smith et al., "Bcl-2 Transcription from the Proximal P2 Promoter Is Activated in Neuronal Cells by the Brn-3a POU Family Transcription Factor", *The*

CHO et al.
U.S. Appln. No.: 10/539,012
INFORMATION DISCLOSURE STATEMENT

Journal of Biological Chemistry, Vol. 273, No. 27, Issue of July 3, 1998, pp. 16715-16722.

4. David W. Hockenbery et al., "BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death", *Pro. Natl. Acad. Sci. USA*, Vol. 88, August 1991, pp. 6961-6965.
5. J. Rodriguez-Villanueva et al., "The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers", *Pathol. Res. Pract.*, Vol. 191, No. 5, June 1995, pp. 391-8.
6. S. Sermadiras et al., "Expression of Bcl-2 and Bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis", *Br. J. Dermatol.*, Vol. 137, No. 6, December 1997, pp. 883-889.
7. Gary J. Fisher et al., "Pathophysiology of Premature Skin Aging Induced by Ultraviolet Light", *The New England Journal of Medicine*, Vol. 337, No. 20, Nov. 13, 1997, pp. 1419-1428.
8. Hidetoshi Takahashi et al., "In Vitro and In Vivo Transfer of bcl-2 Gene into Keratinocytes Suppresses UVB-induced Apoptosis", *Photochemistry and Photobiology*, Vol. 74, No. 4, 2001, pp. 579-586.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

CHO et al.
U.S. Appln. No.: 10/539,012
INFORMATION DISCLOSURE STATEMENT

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 16, 2005

Substitute for Form 1449 A & B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/539,012
			Confirmation Number	Unassigned
Sheet 1 of 1			Filing Date	June 15, 2005
			First Named Inventor	Si-Young CHO
SEP 16 2005 TRADEMARK OFFICE			Art Unit	Unassigned
			Examiner Name	Unassigned
			Attorney Docket Number	Q88600

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Martin D. Smith et al., "Bcl-2 Transcription from the Proximal P2 Promoter Is Activated in Neuronal Cells by the Brn-3a POU Family Transcription Factor", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 27, Issue of July 3, 1998, pp. 16715-16722	
		David W. Hockenbery et al., "BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death", <i>Pro. Natl. Acad. Sci. USA</i> , Vol. 88, August 1991, pp. 6961-6965	
		J. Rodriguez-Villanueva et al., "The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers", <i>Pathol. Res. Pract.</i> , Vol. 191, No. 5, June 1995, pp. 391-8	
		S. Sermadiras et al., "Expression of Bcl-2 and Bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis", <i>Br. J. Dermatol.</i> , Vol. 137, No. 6, December 1997, pp. 883-889	
		Gary J. Fisher et al., "Pathophysiology of Premature Skin Aging Induced by Ultraviolet Light", <i>The New England Journal of Medicine</i> , Vol. 337, No. 20, Nov. 13, 1997, pp. 1419-1428	
		Hidetoshi Takahashi et al., "In Vitro and In Vivo Transfer of bcl-2 Gene into Keratinocytes Suppresses UVB-induced Apoptosis", <i>Photochemistry and Photobiology</i> , Vol. 74, No. 4, 2001, pp. 579-586	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.